News & Trends - Pharmaceuticals

Noxopharm secures $23 million to fund clinical studies in several cancers

Health Industry Hub | December 6, 2020 |
[Total: 1    Average: 4/5]

Pharma News: Australian clinical stage drug development company Noxopharm has successfully completed a A$23 million share placement to professional, institutional and sophisticated investors.

Noxopharm CEO, Dr Graham Kelly said: ”The support received from new, high-quality investors as well as some existing shareholders demonstrates a shared vision in the potential of our technology. That vision is to see Veyonda become the drug of choice to restore cancer-eradicating immune function to tumours, the so-called cold-to-hot effect. This absence of immune function in most human tumours is now recognised as the primary factor holding back current cancer therapies from working to full effect in most patients.

“The significance of what we are doing is that Veyonda, with its unique cold-to-hot effect, is the first opportunity medicine has had of seeing whether this problem can be rectified across a range of major cancer types. If Veyonda proves to be the answer we believe it to be, then the face of cancer therapy is set to change in a dramatic way.”

The funds raised in this placement are intended to provide sufficient runway to show whether that vision can be realised.

The Company is testing the benefit of the cold-to-hot action across three programs:

  1. The first is with checkpoint inhibitors. The IONIC Program is testing Veyonda in combination with the Bristol Myers-Squibb immuno-oncology drug, Opdivo.
  2. The second is with external radiotherapy. The DARRT Program is testing Veyonda in combination with external beam radiotherapy
  3. The third is with intravenous radiotherapy. The LuPIN Program is testing Veyonda in combination with the Novartis’ radiopharmaceutical drug, 177Lu-PSMA-617.

“Planning for both IONIC and DARRT studies has been in the works for many months, but this fresh injection of funds will ensure that both studies can start recruiting patients as soon as possible in the new year. When combined with next year’s anticipated Federal Government R&D Rebate, we expect to be funded through into 2022,” Kelly added.

Use of Funds

Placement proceeds will be applied to the following activities:

  • Commencement of the Phase I/II IONIC-1 study to be conducted in 3 Australian hospitals in 30 patients with a variety of late-stage cancers
  • Commencement of the Phase II DARRT-2 multinational study to be conducted in up to 200 patients with late-stage prostate, breast or lung cancers
  • Completion of the Phase II LuPIN study in 56 men with late-stage prostate cancer
  • Completion of the NOXCOVID-1 study in European hospitals in 40 patients experiencing moderate lung dysfunction associated with COVID-19 disease
  • Two exciting drug discovery programs intended to supply additional first-in-class pipeline drug candidates in the fields of (i) brain cancer, and (ii) pancreatic and gallbladder cancers.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Sustained COVID-19 impact on cancer services and procedures

Sustained COVID-19 impact on cancer services and procedures

Health Industry Hub | January 15, 2021 |

MedTech News: Cancer Australia has released the latest in a series of reports analysing for the first time the significance […]

More


News & Trends - Medical Technology

MedTech News - Healthscope hospital leading in high-tech medical surgery

Healthscope hospital leading in high-tech medical surgery

Health Industry Hub | January 15, 2021 |

MedTech News: Healthscope’s Knox Private Hospital recently celebrated two key milestones, underscoring its reputation as a leading proponent of high-tech […]

More


News & Trends - Pharmaceuticals

Pharma News - Experts comment on AstraZeneca vaccine efficacy concerns

Experts comment on AstraZeneca vaccine efficacy concerns

Health Industry Hub | January 15, 2021 |

Pharma News: In light of the comments made regarding AstraZeneca’s COVID-19 vaccine efficacy by the Australian and New Zealand Society […]

More


Communication

Communication Pharma Biotech Medtech - Secrets of persuasion to influence anyone

Secrets of persuasion to influence anyone

Health Industry Hub | January 15, 2021 |

To understand the art of persuasion, you can turn to cognitive science for guidance in dealing with the unconscious mind. […]

More